NRX Pharmaceuticals
NRXP
17 hedge funds and large institutions have $43.4M invested in NRX Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.17% less ownership
Funds ownership: 4.86% → 4.68% (-0.17%)
4% less capital invested
Capital invested by funds: $45.4M → $43.4M (-$2.04M)
15% less funds holding
Funds holding: 20 → 17 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$4.25M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.9M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.63M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.24M |
| 5 |
BCM
Bluefin Capital Management
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$4.86M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.64M |
| 3 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$2.86M |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$2.73M |
| 5 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$2.16M |
NRXP Hedge Fund Activity: Q2 2019 in Review
17 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2019, worth a combined $43.4M — down 4.5% from $45.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NRXP and 4 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Mizuho Securities USA, adding an estimated $4.25M. The largest seller was HGC Investment Management, exiting entirely with an estimated $4.86M sold.
- 17 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2019, down from 20 in Q1 2019.
- Funds reported $43.4M of NRX Pharmaceuticals stock for Q2 2019, down 4.5% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q2 2019 and 7 closed out, a net change of -3 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2019 was Mizuho Securities USA, an estimated $4.25M added.
- The largest NRX Pharmaceuticals seller in Q2 2019 was HGC Investment Management, an estimated $4.86M sold.
Based on aggregated 13F filings for Q2 2019.